TransMedics TMDX recently announced that it has received full and unconditional FDA Investigational Device Exemption (IDE) approval for its next-generation OCS ENHANCE Heart trial, eliminating a key ...
A magnifying glass. It indicates, "Click to perform a search". A magnifying glass. It indicates, "Click to perform a search". ANDOVER, Mass., April 19, 2022 /PRNewswire/ -- TransMedics Group, Inc.
ANDOVER, Mass., Nov. 4, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with ...
ANDOVER, Mass., Dec. 04, 2019 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Using the Organ Care System (OCS) Heart platform to perfuse, optimize, and assess donor hearts has excellent outcomes, including 87% of extended criteria donor (ECD) hearts being successfully ...
The TransMedics Organ Care System Heart Technology Was Used to Perform The World's First Series of Adult Human Heart Transplants From Donors After Circulatory Death ANDOVER, Massachusetts, Oct. 24 ...
The TransMedics Organ Care System (OCS) Heart System got closer to regulatory approval as it emerged victorious from a contentious FDA advisory committee meeting. Members of the agency's Circulatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results